Key Developments: Bayer AG (BAYGn.DE)

BAYGn.DE on Xetra

127.60EUR
27 Jan 2015
Change (% chg)

-- (--)
Prev Close
€127.60
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,393,514
52-wk High
€130.90
52-wk Low
€91.31

Search Stocks

Latest Key Developments (Source: Significant Developments)

Bayer and Orion initiate phase III trial of ODM-201 in men with high-risk non-metastatic castration-resistant prostate cancer
Tuesday, 16 Sep 2014 02:30am EDT 

Bayer AG:Says together with Orion Corporation initiates phase III trial of ODM-201 in men with high-risk non-metastatic castration-resistant prostate cancer.  Full Article

Janssen Research & Development, LLC and Bayer HealthCare announces results from X-VeRT trial
Tuesday, 2 Sep 2014 02:00am EDT 

Bayer AG:Says Janssen Research & Development, LLC (Janssen) and its development partner, Bayer HealthCare announces results from the X-VeRT trial.X-VeRT trial, demonstrating once-daily XARELTO (rivaroxaban) may be an alternative to vitamin K antagonists (VKA) in treating and reducing the risk of blood clots in non-valvular atrial fibrillation (NVAF) patients undergoing elective cardioversion.X-VeRT trial is the first prospective study of any Factor Xa inhibitor in this high-risk patient population.X-VeRT study results provide physicians with additional insights that may help them manage NVAF patients who are scheduled for cardioversion.X-VeRT explores the potential advantage of using once-daily rivaroxaban as an alternative to VKA therapy to rapidly establish and maintain stable anticoagulation and avoid delays to cardioversion.  Full Article

Quantum Materials Corp acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents
Wednesday, 20 Aug 2014 06:00am EDT 

Quantum Materials Corp:Announces purchase of five diverse sets of patent families from Bayer Technology Services GmbH, global technological backbone and major innovation driver for Bayer AG of Leverkusen, Germany.  Full Article

Bayer AG's Eylea receives European Commission approval for treatment of diabetic macular edema
Monday, 11 Aug 2014 02:30am EDT 

Bayer AG:Says Eylea receives European Commission approval for treatment of diabetic macular edema.Plans for an immediate roll-out with Germany being one of the first launch countries in Europe.  Full Article

Bayer AG raises FY 2014 revenue outlook; reaffirms FY 2014 earnings outlook - Conference Call
Wednesday, 30 Jul 2014 08:00am EDT 

Bayer AG:Expects FY 2014 grow sales organically by about 6 pct compared to the 5 pct previously.Continues to expects to raise FY 2014 EBITDA before special items by a low to mid single digit percentage, allowing for expected negative currency effect of about 550 mln Euros, or roughly 6 pct.Continue to aim to increase FY 2014 core EPS by a mid single digit percentage, allowing for expected negative currency effect of around 9 pct.Reported revenue of 40.157 bln Euros, EBITDA of 8.401 bln Euros, EPS of 5.61 in FY 2013.FY 2014 revenue of 41.806 bln Euros - Thomson Reuters I/B/E/S.  Full Article

Bayer AG's Eylea receives FDA approval for treatment of diabetic macular edema
Wednesday, 30 Jul 2014 03:00am EDT 

Bayer AG:Says Eylea receives FDA approval for treatment of diabetic macular edema.  Full Article

Bayer and Amgen subsidiaries report Phase 3 trial results of NEXAVAR (sorafenib) in patients with advanced breast cancer
Friday, 25 Jul 2014 02:30am EDT 

Bayer AG and Amgen Inc:Says their subsidiaries Bayer HealthCare and Onyx Pharmaceuticals Inc, announces an investigational Phase 3 trial of NEXAVAR (sorafenib) tablets in patients with advanced breast cancer did not meet its primary endpoint of improving progression-free survival.  Full Article

Bayer HealthCare to evaluate Riociguat in new indication
Monday, 2 Jun 2014 08:00pm EDT 

Bayer AG:Bayer HealthCare starts a randomized double-blind, placebo-controlled Phase IIb study with Riociguat in Patients with Symptomatic Pulmonary HypErtension associated with Idiopathic Interstitial Pneumonias.RISE-IIP study is designed to investigate the efficacy and safety of riociguat in patients with symptomatic pulmonary hypertension associated with idiopathic interstitial pneumonia.RISE-IIP trial will be carried out at more than 50 sites in 11 countries and will enroll about 120 patients.  Full Article

Merck & Co Inc announces sale of consumer care business to Bayer AG for $14.2 bln
Tuesday, 6 May 2014 06:00am EDT 

Merck & Co Inc:Enters into definitive agreement to sell its Merck Consumer Care (MCC) business to Bayer AG for $14.2 bln.Bayer AG will acquire Merck's existing OTC business, including global trademark and prescription rights for Claritin and Afrin.Merck expects to close sale of MCC in second half of 2014.Morgan Stanley & Co. LLC acted as financial advisor to Merck, and Fried Frank Harris Shriver & Jacobson LLP and Morgan Lewis & Bockius LLP acted as legal counsel in connection with transaction.J.P. Morgan advised Merck with ongoing portfolio assessment leading up to transaction.Also worldwide clinical development collaboration with Bayer to market and develop its portfolio of soluble guanylate cyclase (sGC) modulators.This includes Bayer's Adempas (riociguat), the first member of this novel class of compounds.Collaboration also includes clinical development of vericiguat (BAY102), which is currently in Phase 2 trials for worsening heart failure, as well as opt-in rights for other early-stage sGC compounds in development at Bayer.Merck will in turn make available its early-stage sGC compounds under similar terms.  Full Article

Bayer AG confirms FY 2014 outlook - Reuters
Monday, 28 Apr 2014 02:17am EDT 

Bayer AG:Confirms FY 2014 outlook for low to medium single digit percentage rise in adjusted EBITDA - Reuters.Confirms FY 2014 outlook for currency adjusted sales of around 41-42 billion euros.FY 2014 revenue estimate 41.906 billion euros - Thomson Reuters I/B/E/S.  Full Article

BRIEF-Bayer study to evaluate Xarelto in stroke patients

* Bayer forms collaboration with academic and governmental institutions for global phase III study to evaluate Xarelto

Search Stocks